A novel dual-action small molecule developed by a team led by scientists at Kyungpook National University (KNU) in Daegu, South Korea, has been shown to improve the neuropathological features of Alzheimer's disease (AD) in mice, the authors reported in the Jan. 18, 2022, edition of Proceedings of the National Academy of Sciences.